End-to-End Platform for Human Pluripotent Stem Cell Manufacturing
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Industrialization of stem-cell based therapies requires innovative solutions to close the gap between research and commercialization. Scalable cell production platforms are needed to reliably deliver the cell quantities needed during the various stages of development and commercial supply. Human pluripotent stem cells (hPSCs) are a key source material for generating therapeutic cell types. We have developed a closed, automated and scalable stirred tank bioreactor platform, capable of sustaining high fold expansion of hPSCs. Such a platform could facilitate the in-process monitoring and integration of online monitoring systems, leading to significantly reduced labor requirements and contamination risk. hPSCs are expanded in a controlled bioreactor using perfused xeno-free media. Cell harvest and concentration are performed in closed steps. The hPSCs can be cryopreserved to generate a bank of cells, or further processed as needed. Cryopreserved cells can be thawed into a two-dimensional (2D) tissue culture platform or a three-dimensional (3D) bioreactor to initiate a new expansion phase, or be differentiated to the clinically relevant cell type. The expanded hPSCs express hPSC-specific markers, have a normal karyotype and the ability to differentiate to the cells of the three germ layers. This end-to-end platform allows a large scale expansion of high quality hPSCs that can support the required cell demand for various clinical indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While culturing iPSCs as aggregates involves 2D to 3D adaptation and frequent cell passaging to control the size of the cell aggregates, the cells could be directly used for downstream processes such as cryopreservation and differentiation [79,81].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this process, iPSCs were cultured in agitation, on microcarriers, with no passaging for 12–14 days, followed by steps of dissociation from the”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An end-to-end process of thawing and expanding iPSCs in a stirred tank bioreactor was recently described [81].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Culturing iPSCs in a stirred tank bioreactor on microcarriers could be an attractive way to achieve large cell quantities in a relatively short time, without the need for 2D to 3D adaptation or passaging [81].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 1×
“Successful generation of human-induced pluripotent stem cells (hiPSCs) by somatic cell reprogramming has opened new avenues in regenerative medicine, disease modeling and drug development [1,2].”
BackgroundLian, X., Zhang, J., Azarin, S. M., Zhu, K., Hazeltine, L. B., Bao, X., Hsiao, C., Kamp, T. J., & Palecek, S. P. (2013) · Nature Protocols · doi:10.1038/nprot.2012.150 · Cited by 1,748 · cited 2×
“Human iPSCs were differentiated into cardiomyocytes using the Gsk3 inhibitor and Wnt inhibitor (GiWi) protocol as previously described [5,40,41].”
BackgroundMethodLian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L. B., Azarin, S. M., Raval, K. K., Zhang, J., Kamp, T. J., & Palecek, S. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200250109 · Cited by 1,717 · cited 1×
“Human iPSCs were differentiated into cardiomyocytes using the Gsk3 inhibitor and Wnt inhibitor (GiWi) protocol as previously described [5,40,41].”
Functional Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells
Zhang, J., Wilson, G. F., Soerens, A. G., Koonce, C. H., Yu, J., Palecek, S. P., Thomson, J. A., & Kamp, T. J. (2009) · Circulation Research · doi:10.1161/circresaha.108.192237 · Cited by 1,407 · cited 1×
“Human iPSCs were differentiated into cardiomyocytes using the Gsk3 inhibitor and Wnt inhibitor (GiWi) protocol as previously described [5,40,41].”
MethodThe promise of induced pluripotent stem cells in research and therapy
Robinton, D. A., & Daley, G. Q. (2012) · Nature · doi:10.1038/nature10761 · Cited by 1,111 · cited 1×
“Capable of self-renewal and pluripotency, hiPSCs derived from patients of both normal and aberrant phenotypes provide a theoretically limitless supply of clinically relevant iPSC-derived cells without ethical limitations and immune-rejection [3,4].”
BackgroundEngineering Adolescence: Maturation of Human Pluripotent Stem Cell–Derived Cardiomyocytes
Yang, X., Pabon, L., & Murry, C. E. (2014) · Circulation Research · doi:10.1161/circresaha.114.300558 · Cited by 939 · cited 1×
“Moreover, iPSC-derived cardiomyocytes remain phenotypically immature [8], despite a number of studies demonstrating enhanced maturation through the modulation of existing methodologies [9–13].”
BackgroundOkita, K., Yamakawa, T., Matsumura, Y., Sato, Y., Amano, N., Watanabe, A., Goshima, N., & Yamanaka, S. (2013) · Stem Cells · doi:10.1002/stem.1293 · Cited by 749 · cited 1×
“To reprogram the cells, 1× 106 PBMNCs were nucleofected with the episomal plasmids pCE-hOCT3/4, pCE-hSK, pCE-hUL, pCE-mP53DD and pCXB-EBNA-1 [37].”
MethodMummery, C. L., Zhang, J., Ng, E. S., Elliott, D. A., Elefanty, A. G., & Kamp, T. J. (2012) · Circulation Research · doi:10.1161/circresaha.110.227512 · Cited by 713 · cited 2×
“To replace the number of cells lost during a myocardial infarction, for example, approximately 1 × 109 cells are required per patient dose [7].”
BackgroundYang, X., Rodriguez, M., Pabon, L., Fischer, K. A., Reinecke, H., Regnier, M., Sniadecki, N. J., Ruohola-Baker, H., & Murry, C. E. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.04.005 · Cited by 431
Parikh, S. S., Blackwell, D. J., Gomez-Hurtado, N., Frisk, M., Wang, L., Kim, K., Dahl, C. P., Fiane, A., Tønnessen, T., Kryshtal, D. O., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311920 · Cited by 376
Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics
Chen, K. G., Mallon, B. S., McKay, R. D. G., & Robey, P. G. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2013.12.005 · Cited by 358 · cited 1×
“Over the past decade, efforts toward the development and optimization of cGMP compliant, large-scale manufacturing of cell-based therapies have significantly increased [15,28].”
BackgroundFatty Acids Enhance the Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells
Yang, X., Rodriguez, M. L., Leonard, A., Sun, L., Fischer, K. A., Wang, Y., Ritterhoff, J., Zhao, L., Kolwicz, S. C., Pabon, L., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.08.013 · Cited by 304
Translation of Human-Induced Pluripotent Stem Cells
Sayed, N., Liu, C., & Wu, J. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.083 · Cited by 279 · cited 1×
“Capable of self-renewal and pluripotency, hiPSCs derived from patients of both normal and aberrant phenotypes provide a theoretically limitless supply of clinically relevant iPSC-derived cells without ethical limitations and immune-rejection [3,4].”
BackgroundBaghbaderani, B. A., Tian, X., Neo, B. H., Burkall, A., Dimezzo, T., Sierra, G., Zeng, X., Warren, K., Kovarcik, D. P., Fellner, T., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.08.015 · Cited by 212 · cited 1×
“Quantitative detection of hPSC-associated markers was performed using flow cytometry as previously described [16,38,39].”
MethodSuspension Culture of Human Pluripotent Stem Cells in Controlled, Stirred Bioreactors
Olmer, R., Lange, A., Selzer, S., Kasper, C., Haverich, A., Martin, U., & Zweigerdt, R. (2012) · Tissue Engineering Part C: Methods · doi:10.1089/ten.tec.2011.0717 · Cited by 202 · cited 1×
“A number of studies have demonstrated the feasibility of hPSC expansion in suspension cultures using aggregate [14,16,17] and microcarrier (MC)-based [18–20] three dimensional (3D) culture systems.”
BackgroundLock, L. T., & Tzanakakis, E. S. (2009) · Tissue Engineering Part A · doi:10.1089/ten.tea.2008.0455 · Cited by 183
Feaster, T. K., Cadar, A. G., Wang, L., Williams, C. H., Chun, Y. W., Hempel, J. E., Bloodworth, N., Merryman, W. D., Lim, C. C., Wu, J. C., et al. (2015) · Circulation Research · doi:10.1161/circresaha.115.307580 · Cited by 177
Scalable culture and cryopreservation of human embryonic stem cells on microcarriers
Nie, Y., Bergendahl, V., Hei, D. J., Jones, J. M., & Palecek, S. P. (2009) · Biotechnology Progress · doi:10.1002/btpr.110 · Cited by 175
Progress and challenges in large-scale expansion of human pluripotent stem cells
Kropp, C., Massai, D., & Zweigerdt, R. (2017) · Process Biochemistry · doi:10.1016/j.procbio.2016.09.032 · Cited by 167 · cited 3×
“Not without its own advantages, microcarrier-based culture systems facilitate a larger surface area to volume ratio for scalability, provide large surface area for adhesion and growth during expansion, flexibility in using defined extracellular matrices, and allow the maintenance of homogenous culture conditions [15,1…”
BackgroundScalable GMP compliant suspension culture system for human ES cells
Chen, V. C., Couture, S., Ye, J., Lin, Z., Hua, G., Huang, H.-I. P., Wu, J., Hsu, D. S., Carpenter, M. K., & Couture, L. A. (2012) · Stem Cell Research · doi:10.1016/j.scr.2012.02.001 · Cited by 160 · cited 2×
“Aggregate-based 3D culture provides a more physiologically relevant microenvironment, but has been shown not only to require the small molecule, Y27632, for the survival of hPSCs [15], but also sequential passaging to achieve high fold expansion [21].”
BackgroundResultSerra, M., Brito, C., Sousa, M. F. Q., Jensen, J., Tostões, R. M., Clemente, J. J., Strehl, R., Hyllner, J., Carrondo, M. J. T., & Alves, P. M. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.06.015 · Cited by 150 · cited 1×
“Others have also shown that 30% DO is the optimal condition to support hPSC expansion [33].”
BackgroundOtsuji, T. G., Bin, J., Yoshimura, A., Tomura, M., Tateyama, D., Minami, I., Yoshikawa, Y., Aiba, K., Heuser, J. E., Nishino, T., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.03.012 · Cited by 136 · cited 2×
“Conve tion l expansion of hPSCs in 3D culture pr marily relies on 2D-cultured cell inocu um [17,20,22].”
BackgroundBatalov, I., & Feinberg, A. W. (2015) · Biomarker Insights · doi:10.4137/bmi.s20050 · Cited by 124 · cited 1×
“For instance, given the heart’s limited-to-no regenerative capacity, new cardiomyocytes can be derived from hiPSCs by modulating developmental cues critical in embryonic development in vivo [5,6].”
BackgroundWakeman, D. R., Hiller, B. M., Marmion, D. J., McMahon, C. W., Corbett, G. T., Mangan, K. P., Ma, J., Little, L. E., Xie, Z., Perez‐Rosello, T., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.04.033 · Cited by 90
Baghbaderani, B. A., Syama, A., Sivapatham, R., Pei, Y., Mukherjee, O., Fellner, T., Zeng, X., & Rao, M. S. (2016) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9662-8 · Cited by 86 · cited 1×
“The human LiPSC18R induced pluripotent stem cells (iPSC) line was generated from CD34+ cord blood cells as previously described [36].”
MethodBadenes, S. M., Fernandes, T. G., Cordeiro, C. S. M., Boucher, S., Kuninger, D., Vemuri, M. C., Diogo, M. M., & Cabral, J. M. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151264 · Cited by 81 · cited 3×
“Not without its own advantages, microcarrier-based culture systems facilitate a larger surface area to volume ratio for scalability, provide large surface area for adhesion and growth during expansion, flexibility in using defined extracellular matrices, and allow the maintenance of homogenous culture conditions [15,1…”
BackgroundMorphologic and Gene Expression Criteria for Identifying Human Induced Pluripotent Stem Cells
Wakao, S., Kitada, M., Kuroda, Y., Ogura, F., Murakami, T., Niwa, A., & Dezawa, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048677 · Cited by 64 · cited 2×
“Me while, cell-MC clusters plated directly onto 2D culture plates without releasing the cells as single cells, exhibited typical hPSC colony morphology, including defined edges [23] and tightly packed cells with large nuclei and scant cytoplasm (Figure 5B, right panel) [1].”
BackgroundAutomated real-time monitoring of human pluripotent stem cell aggregation in stirred tank reactors
Schwedhelm, I., Zdzieblo, D., Appelt-Menzel, A., Berger, C., Schmitz, T., Schuldt, B., Franke, A., Müller, F.-J., Pless, O., Schwarz, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48814-w · Cited by 44 · cited 4×
“A number of studies have demonstrated the feasibility of hPSC expansion in suspension cultures using aggregate [14,16,17] and microcarrier (MC)-based [18–20] three dimensional (3D) culture systems.”
BackgroundInfluentialSilva, M. M., Rodrigues, A. F., Correia, C., Sousa, M. F. Q., Brito, C., Coroadinha, A. S., Serra, M., & Alves, P. M. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0270 · Cited by 40
Shafa, M., Yang, F., Fellner, T., Rao, M. S., & Baghbaderani, B. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00069 · Cited by 36
Guo, C., Kawakatsu, M., Idemitsu, M., Urata, Y., Goto, S., Ono, Y., Hamano, K., & Li, T. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24389 · Cited by 35
Oxygen Regulates Human Pluripotent Stem Cell Metabolic Flux
Lees, J. G., Cliff, T. S., Gammilonghi, A., Ryall, J. G., Dalton, S., Gardner, D. K., & Harvey, A. J. (2019) · Stem Cells International · doi:10.1155/2019/8195614 · Cited by 33
Shafa, M., Panchalingam, K. M., Walsh, T., Richardson, T., & Baghbaderani, B. A. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27159 · Cited by 31
Oxygen modulates human embryonic stem cell metabolism in the absence of changes in self-renewal
Harvey, A. J., Rathjen, J., Yu, L. J., & Gardner, D. K. (2014) · Reproduction Fertility and Development · doi:10.1071/rd14013 · Cited by 30
Lam, A. T.-L., Li, J., Chen, A. K.-L., Birch, W. R., Reuveny, S., & Oh, S. K.-W. (2015) · BioResearch Open Access · doi:10.1089/biores.2015.0010 · Cited by 27 · cited 2×
“Results were comparable to those previously published when assessing hESC growth on laminin-coated MCs [19].”
BackgroundResultCryopreservation of Induced Pluripotent Stem Cells
Miyamoto, Y., Noguchi, H., Yukawa, H., Oishi, K., Matsushita, K., Iwata, H., & Hayashi, S. (2012) · Cell Medicine · doi:10.3727/215517912x639405 · Cited by 25 · cited 1×
“A key hurdle, however, is maintaining the viability and performance of cryopreserved cells [24].”
BackgroundThe silver lining of induced pluripotent stem cell variation
Fossati, V., Jain, T., & Sevilla, A. (2016) · Stem Cell Investigation · doi:10.21037/sci.2016.11.16 · Cited by 25 · cited 1×
“Moreover, given the variability typically observed between the cell lines [27], culture of hPSCs by a 2D seed train depends on subjective decision making, and often requires highly-trained personnel, capable of monitoring for culture irregularities, which could adversely impact subsequent cell expansion in a bioreacto…”
BackgroundPreininger, M. K., Singh, M., & Xu, C. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-45457-3_10 · Cited by 22 · cited 1×
“Another key element in the large-scale manufacturing of cell-based therapies is maintaining the viability of cryopreserved cells, such that the therapeutic potential of these cells remains intact [25].”
BackgroundEffect of inoculum density on human‐induced pluripotent stem cell expansion in 3D bioreactors
Greuel, S., Hanci, G., Böhme, M., Miki, T., Schubert, F., Sittinger, M., Mandenius, C., Zeilinger, K., & Freyer, N. (2019) · Cell Proliferation · doi:10.1111/cpr.12604 · Cited by 17 · cited 3×
“We successfully produced 6–15 × 109 cells per 3 L bioreactor run, (cell line and harvest day-dependent) meeting the number of cells required for a number of clinical indications [29].”
BackgroundMethodResultBadenes, S. M., Fernandes, T. G., Cordeiro, C. S. M., Boucher, S., Kuninger, D., Vemuri, M. C., Diogo, M. M., & Cabral, J. M. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155296 · Cited by 14
Ahmadian Baghbaderani, B., Tian, X., Scotty Cadet, J., Shah, K., Walde, A., Tran, H., Kovarcik, D. P., Clarke, D., & Fellner, T. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161229 · Cited by 13 · cited 1×
“The Lonza L7TM culture system was developed specifically for culturing human embryonic stem cells (hESCs) and human-induced pluripotent stem cells (hiPSCs) in a feeder-free environment [35].”
MethodBespoke cell therapy manufacturing platforms
Levinson, Y., Beri, R. G., Holderness, K., Ben‐Nun, I. F., Shi, Y., & Abraham, E. (2018) · Biochemical Engineering Journal · doi:10.1016/j.bej.2018.01.023 · Cited by 10
Self-citationCadar, A. G., Feaster, T. K., Durbin, M. D., & Hong, C. C. (2017) · Current Protocols in Stem Cell Biology · doi:10.1002/cpsc.32 · Cited by 7
Baptista, R. P., Popova, D., Macown, R. J., Senderovich, S., Nicholas, N., François, M., Grandolfo, D., Schena, I., Gaddum, N. R., Baradez, M., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.02.354 · Cited by 1
Ben‐Nun, I. F. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.03.328 · Cited by 1
Cited by
Chen, H., Deng, J., Yao, X., He, Y., Li, H., Jian, Z., Tang, Y., Zhang, X., Zhang, J., & Dai, H. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01088-9 · Cited by 74
Advances in automated cell washing and concentration
Li, A., Kusuma, G. D., Driscoll, D., Smith, N., Wall, D. M., Levine, B. L., James, D., & Lim, R. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.04.003 · Cited by 49
Rivera-Ordaz, A., Peli, V., Manzini, P., Barilani, M., & Lazzari, L. (2021) · BioDrugs · doi:10.1007/s40259-021-00503-9 · Cited by 47
Schwertfirm, G., Schneider, M. C., Haase, F., Riedel, C., Lazzaro, M., Ruge‐Wehling, B., & Schweizer, G. (2024) · Theoretical and Applied Genetics · doi:10.1007/s00122-024-04665-2 · Cited by 44
Boussaad, I., Cruciani, G., Bolognin, S., Antony, P., Dording, C. M., Kwon, Y.-J., Heutink, P., Fava, E., Schwamborn, J. C., & Krüger, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-81129-3 · Cited by 42
“(1) Liquid handler Biomek NX Span-8 including the plate shaker Shaking Peltier ALP and a tilting station Amplius (AIG) 3D Tilting ALP, (2) Liquid handler Biomek FXP (96- and 384-pipetting head including active wash-station and a BioShake 3000, (3) Acoustic droplet ejector Labcyte Echo550, (4) High content imager Yokog…”
Method
Metadata
- Authors
- Pandey, P. R., Tomney, A., Woon, M. T., Uth, N., Shafighi, F., Ngabo, I., Vallabhaneni, H., Levinson, Y., Abraham, E., & Friedrich Ben-Nun, I.
- Affiliations
- Lonza (United States) (US)
- Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-12-21
- Volume
- 21
- Issue
- 1
- Pages
- 89
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6981419
- OpenAlex
- W2995477520
- Cited by
- 42
- References
- 46
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 2 · 2019: 1
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- human pluripotent stem cells, stem cell manufacturing, stirred tank bioreactor, cell cryopreservation, cell banking, stem cell differentiation, three germ layers, contamination risk reduction
- MeSH terms
- Cellular Reprogramming Techniques, Cell Differentiation, Cells, Cultured, Humans, Bioreactors, Myocytes, Cardiac, Cell Proliferation, Induced Pluripotent Stem Cells, Automation, Laboratory, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.